Established Cardiovascular Disease Annual Evaluation Checklist

What Does "Established Cardiovascular Disease" Mean Clinically?

Established cardiovascular disease (CVD) is defined as documented atherosclerotic disease causing clinical events or symptoms. This includes prior myocardial infarction, ischemic stroke or TIA, peripheral arterial disease, stable or unstable angina, or coronary revascularization by PCI or CABG. These patients fall into the very-high or high atherosclerotic cardiovascular risk categories under both AHA/ACC and ESC frameworks.

Why the Distinction Matters

The distinction between primary and secondary prevention changes every treatment threshold. Statins, antiplatelets, ACE inhibitors, and beta-blockers each carry different evidence weights and initiation criteria once a patient crosses into established disease. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly separates its recommendations from secondary-prevention guidance precisely because the benefit-risk math shifts [1].

Who Should Use This Checklist

This checklist applies to any adult with at least one qualifying atherosclerotic event. Patients with heart failure without obstructive coronary disease, lone atrial fibrillation, or hypertensive heart disease without documented atherosclerosis follow different protocols and are not the target audience here.

The 10-Domain Annual Evaluation Checklist

A structured annual visit for established CVD should cover ten clinical domains. Skipping any domain risks missing actionable findings that directly increase MACE probability.

Domain 1: LDL Cholesterol and Lipid Panel

LDL-C is the single most actionable bioavailable biomarker in secondary prevention. The 2018 AHA/ACC Cholesterol Guideline recommends a fasting lipid panel at every annual visit, with an LDL-C target of <70 mg/dL for very-high-risk patients and <55 mg/dL under the stricter 2019 ESC/EAS Dyslipidaemia Guidelines [2, 3].

Statin Therapy Audit

Confirm the patient is on high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) unless contraindicated. The PROVE-IT TIMI 22 trial (N=4,162) demonstrated that intensive atorvastatin 80 mg reduced the composite of death, MI, or urgent revascularization by 16% compared with pravastatin 40 mg at 24 months (P<0.005) [4].

Ezetimibe and PCSK9 Inhibitors

If LDL-C remains above target on maximally tolerated statin, add ezetimibe 10 mg. IMPROVE-IT (N=18,144) showed ezetimibe added to simvastatin reduced cardiovascular events by an absolute 2% over 7 years [5]. For patients still above target, PCSK9 inhibitors (evolocumab, alirocumab) reduce LDL-C by 50 to 60% on top of statin therapy and reduce MACE. FOURIER (N=27,564) found evolocumab reduced the primary endpoint by 15% relative to placebo over a median of 2.2 years [6].

Lipoprotein(a) Screening

Measure Lp(a) at least once in all established CVD patients. Lp(a) above 50 mg/dL independently increases MACE risk and is not lowered by statins. This measurement informs future eligibility for RNA-based therapies in development.

Domain 2: Blood Pressure

The 2017 AHA/ACC High Blood Pressure Guideline sets a target of <130/80 mmHg for patients with confirmed atherosclerotic CVD [7]. Every 10 mmHg reduction in systolic blood pressure reduces the risk of major cardiovascular events by approximately 20% across a broad population of high-risk patients, according to the Blood Pressure Lowering Treatment Trialists' Collaboration (N=123,000 pooled) [8].

Drug Class Priorities

ACE inhibitors or ARBs are first-line post-MI and in patients with reduced ejection fraction. Beta-blockers are first-line in the 12 months post-MI and in those with heart failure with reduced EF. Thiazide or thiazide-like diuretics (chlorthalidone 12.5 to 25 mg) add incremental benefit in resistant hypertension. Avoid dual RAS blockade (ACE inhibitor plus ARB) outside of specific proteinuric CKD protocols.

Home Blood Pressure Monitoring

Instruct patients to perform home blood pressure measurements on at least 3 separate days (morning and evening, two readings each) before every clinic visit. White-coat hypertension is present in up to 30% of clinic readings and leads to unnecessary intensification.

Domain 3: Antiplatelet and Antithrombotic Therapy

Antiplatelet therapy is the backbone of secondary prevention. Aspirin 75 to 100 mg daily reduces the risk of recurrent MI by approximately 25% in high-risk secondary prevention patients, per the Antithrombotic Trialists' Collaboration meta-analysis (N=135,000 patient-years) [9].

Dual Antiplatelet Therapy Duration

After PCI with drug-eluting stent implantation, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is standard for 6 to 12 months. After this window, confirm whether de-escalation or aspirin monotherapy is appropriate based on ischemic and bleeding risk scoring (PRECISE-DAPT, DAPT Score). Record DAPT status at each annual visit.

Aspirin-Intolerant Patients

Clopidogrel 75 mg daily is the recommended alternative. CAPRIE (N=19,185) showed clopidogrel was at least as effective as aspirin 325 mg for reducing the combined endpoint of ischemic stroke, MI, or vascular death, with a small but statistically significant relative risk reduction of 8.7% in favor of clopidogrel (P=0.043) [10].

Domain 4: Glycemic Status

Prediabetes affects 37% of adults with established CVD in some registry data, and undiagnosed type 2 diabetes is common in this population. Obtain a fasting plasma glucose and HbA1c annually. An HbA1c of 5.7 to 6.4% triggers lifestyle counseling and repeat testing in 12 months; HbA1c 6.5% or above on two occasions confirms type 2 diabetes and changes the medication algorithm.

GLP-1 Receptor Agonists in Established CVD

The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg weekly reduced the primary MACE endpoint (cardiovascular death, non-fatal MI, or non-fatal stroke) by 20% versus placebo in adults with overweight or obesity (BMI 27 or above) and established CVD but without diabetes, over a mean follow-up of 39.8 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [11]. This was the first GLP-1 receptor agonist cardiovascular outcome trial conducted entirely in a non-diabetic population.

The FDA approved semaglutide (Wegovy) for cardiovascular risk reduction in March 2024 specifically on the basis of SELECT. For established CVD patients with BMI 27 or above, GLP-1 RA therapy is now a guideline-concordant option independent of diabetes status.

SGLT2 Inhibitors

In patients with type 2 diabetes and established CVD, SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) reduce cardiovascular death and hospitalization for heart failure. EMPA-REG OUTCOME (N=7,020) showed empagliflozin reduced cardiovascular death by 38% versus placebo (HR 0.62; 95% CI 0.49 to 0.77; P<0.001) [12]. Confirm SGLT2 inhibitor use in all diabetic CVD patients without contraindication.

Domain 5: Renal Function

Chronic kidney disease (CKD) is both a risk factor for cardiovascular events and a consequence of long-standing hypertension and atherosclerosis. Obtain serum creatinine with calculated eGFR and a urine albumin-to-creatinine ratio (uACR) annually. CKD stage G3 or above (eGFR <60 mL/min/1.73m²) or uACR above 30 mg/g modifies drug dosing and triggers nephrology co-management.

EGFR below 30 mL/min/1.73m² contraindicates metformin and SGLT2 inhibitors and may reduce rosuvastatin dosing. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces composite CKD and cardiovascular events in diabetic CKD patients as shown in FIDELIO-DKD (N=5,734) [13].

Domain 6: Weight and Body Composition

Obesity worsens every modifiable CVD risk factor. A 5 to 10% reduction in body weight improves LDL-C, blood pressure, fasting glucose, and inflammatory markers. The SELECT trial data confirm that intentional weight loss through pharmacotherapy provides a MACE benefit beyond weight loss alone, given that cardiovascular risk reduction with semaglutide began within 3 months, well before significant weight loss accrued.

BMI and Waist Circumference

Measure BMI and waist circumference at every annual visit. Abdominal obesity (waist circumference above 102 cm in men, above 88 cm in women) confers additional cardiometabolic risk even when overall BMI falls in the overweight range. Document both values and trend them year over year.

Pharmacotherapy Thresholds

For established CVD patients with BMI 27 or above, semaglutide 2.4 mg weekly now carries an FDA indication for cardiovascular risk reduction. For BMI 30 or above with obesity-related comorbidities, the 2023 American Heart Association Obesity and Cardiovascular Disease guideline recommends discussing both lifestyle and pharmacotherapy [14].

Domain 7: Smoking and Substance Use

Smoking cessation after MI reduces the risk of recurrent MI by approximately 50% within the first year, a benefit comparable to most pharmacotherapy interventions used in secondary prevention [15]. Screen at every annual visit using a single validated question: "Do you currently smoke cigarettes, even occasionally?"

Cessation Pharmacotherapy

Varenicline (2 mg/day) remains the most effective single pharmacotherapy for smoking cessation, with abstinence rates approximately double those of nicotine replacement therapy in meta-analyses. Earlier safety concerns about psychiatric adverse events were refuted in the EAGLES trial (N=8,144) [16]. For patients with a recent ACS, start cessation therapy before hospital discharge.

Electronic cigarettes are not recommended as a cessation tool in established CVD patients due to insufficient safety data specific to this population.

Domain 8: Physical Activity and Cardiac Rehabilitation

Cardiac rehabilitation is consistently under-prescribed. A Cochrane meta-analysis of exercise-based cardiac rehabilitation (N=14,486 patients across 63 trials) found a 26% reduction in cardiovascular mortality and a 31% reduction in hospital admissions compared with usual care [17].

Referral Criteria

Every post-MI, post-CABG, or post-PCI patient qualifies for Phase II cardiac rehabilitation. Referral rates in the United States remain below 50% despite class I recommendations. Confirm at every annual visit whether the patient completed a program and whether they are maintaining an exercise habit.

Ongoing Exercise Prescription

The AHA recommends at least 150 minutes per week of moderate-intensity aerobic activity or 75 minutes per week of vigorous activity for secondary prevention. Document exercise habits using a simple validated tool (FITT: Frequency, Intensity, Type, Time) at each annual visit.

Domain 9: Cardiac Imaging and Functional Testing

Routine annual cardiac imaging is not recommended for asymptomatic stable patients. However, specific clinical triggers warrant timely testing.

Echocardiography Indications

Repeat echocardiography is indicated if the patient has new or worsening dyspnea, palpitations, or signs of heart failure. For patients with known reduced EF (EF <50%), echocardiography every 1 to 2 years monitors response to guideline-directed medical therapy. Unchanged stable symptoms with normal prior imaging do not justify repeat echo by AUC (Appropriate Use Criteria) criteria.

Stress Testing

Stress testing is appropriate for patients with new exertional symptoms, not as routine surveillance. The 2012 ACCF/AHA appropriate use criteria for diagnostic catheterization advise against routine angiography in asymptomatic post-revascularization patients.

Ankle-Brachial Index

For patients with peripheral arterial disease, measure the ankle-brachial index (ABI) annually. An ABI below 0.9 confirms PAD; an ABI below 0.7 suggests moderate-to-severe disease warranting vascular surgery co-management.

Domain 10: Psychosocial Health and Medication Adherence

Depression affects approximately 20% of post-MI patients and independently doubles 12-month MACE risk. Screen annually using the PHQ-9. The 2014 AHA Scientific Statement on Depression and Coronary Heart Disease recommends routine screening and treatment referral, noting that sertraline and citalopram have demonstrated safety in CVD patients (SADHART trial, ENRICHD trial) [18].

Medication Adherence

Non-adherence to secondary prevention medications causes an estimated 125,000 deaths annually in the United States. At each annual visit, use a brief validated adherence screen (Morisky-8 or single-question adherence screen) and reconcile the medication list against current fills.

The table below summarizes the annual checklist across all ten domains with action thresholds.

| Domain | Annual Test | Action Threshold | |---|---|---| | Lipids | Fasting lipid panel | LDL-C >70 mg/dL: intensify therapy | | Blood pressure | Office + home BP average | SBP >130 or DBP >80: titrate medications | | Antiplatelet | Medication reconciliation | Confirm aspirin 75 to 100 mg or clopidogrel 75 mg | | Glycemia | HbA1c + fasting glucose | HbA1c >6.5%: diabetes diagnosis; >5.6%: counsel | | Renal function | eGFR + uACR | eGFR <60 or uACR >30: modify drug regimen | | Weight | BMI + waist circumference | BMI >27 + CVD: discuss GLP-1 RA | | Smoking | Validated single question | Any smoking: offer varenicline | | Exercise | FITT documentation | <150 min/week moderate activity: prescribe rehab | | Cardiac imaging | Symptom-triggered | New symptoms: echo or stress test | | Psychosocial | PHQ-9 | Score >10: refer for treatment |

GLP-1 Receptor Agonists: A New Pillar of Secondary Prevention

The SELECT trial data represent a meaningful shift in how clinicians should think about weight management in established CVD. Dr. A. Michael Lincoff, the principal investigator of SELECT, stated in the NEJM publication: "Semaglutide was superior to placebo in reducing the risk of serious cardiovascular events in patients with preexisting cardiovascular disease and either overweight or obesity" [11]. This positions semaglutide not merely as a weight-loss drug but as a cardiovascular risk-reduction agent in its own right.

The 2023 AHA/ACC Guideline on Chronic Coronary Disease now lists GLP-1 RAs as a class IIa recommendation for patients with established CVD who have overweight or obesity. Combined with the FDA's March 2024 labeling change for semaglutide 2.4 mg, the prescribing barrier for this population has been substantially reduced.

For patients already on maximum-intensity statin plus antiplatelet therapy with well-controlled blood pressure, adding a GLP-1 RA (if BMI 27 or above) represents one of the few remaining interventions with trial-proven additional MACE reduction in this population.

How to Manage Established Cardiovascular Disease: Year-Round Priorities

Annual evaluation is a checkpoint, not the full extent of management. Between annual visits, patients with established CVD need three standing instructions.

Symptom Recognition and Emergency Response

Every patient should know the five warning signs of MI (chest pressure, jaw or left arm pain, shortness of breath, diaphoresis, nausea) and stroke (FAST: Face drooping, Arm weakness, Speech difficulty, Time to call 911). Written materials improve recall by approximately 40% compared with verbal-only instruction alone.

Medication Self-Management

Patients should carry a current medication list and understand that stopping a statin or antiplatelet without physician guidance carries measurable risk. Statin discontinuation in the year after MI is associated with a 2.3-fold increase in all-cause mortality, per observational data from the PREMIER registry.

Diet: Mediterranean or DASH Pattern

The PREDIMED trial (N=7,447) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced the composite of MI, stroke, and cardiovascular death by 30% relative to a low-fat control diet over approximately 5 years [19]. Provide a written dietary handout or dietitian referral at each annual visit.